Immunological Efficacy of a Three-Dose Schedule of Hepatitis A Vaccine in HIV-Infected Adults: HEPAVAC Study
Odile Launay(Hôpital Cochin), David Rey, Dominique Salmon‐Céron(Délégation Paris 5), Linda Bélarbi(Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale), Jérôme Dimet(Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale), David Jegou(Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale), Corinne Desaint(Assistance Publique – Hôpitaux de Paris), Sophie Grabar(Délégation Paris 5), Emmanuel Gordien(Inserm), Sébastien Abad(Assistance Publique – Hôpitaux de Paris), Olivier Lortholary(Assistance Publique – Hôpitaux de Paris), Corinne Guérin(Groupe Hospitalier Cochin - Port-Royal, Hôtel-Dieu, Broca - La Collégiale), Anne Krivine(Hôpital Cochin), Virginie Williams(Inserm), Pierre‐Marie Girard
Cited by 71
Related Papers
Tuberculosis in HIV-infected patients: a comprehensive review
|Clinical Microbiology and Infection|2004|332
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial
|The Lancet. Gastroenterology & hepatology|2017|249
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection
|EBioMedicine|2021|239